Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs KB Financial Group, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while KB Financial Group, Inc. trades at $117.53 (market cap $41.21B). The key difference: KB Financial Group, Inc. is the larger of the two by market cap, and KB Financial Group, Inc. pays a 2.67% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KB | |
|---|---|---|
Market Cap | $29.60B | $41.21B |
Sector | Health | Financials |
52-Week High | $491.22 | $124.01 |
52-Week Low | $205.48 | $77.50 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
KB Financial trades at $117.85, down 2.39% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.36, P/B of 0.98, and net income margin of 27.82%. Recent earnings beats in Q1 and Q2 2026 highlight operational strength, while cash flow trends show variability with a net inflow of $4.41T in 2025.
The outlook is positive given earnings momentum and undervaluation relative to peers, but risks include volatile cash flows and dependence on interest rates. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism for upside potential amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
